TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00604435

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel and epirubicin
Description: docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and epirubicin plus endostatin
Description: docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
Study: NCT02720653

Intervention type: PROCEDURE
Intervention: Endoscopic sinus surgery
Study: NCT04043715

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcutaneous spinal stimulation
Description: Physical therapy to improve standing and walking

Intervention type: DEVICE
Group type: OTHER
Intervention: Epidural spinal stimulation
Description: Physical therapy to improve standing and walking
Study: NCT00745953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 320mg PO daily for 8 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25mg PO daily for 8 months
Study: NCT02637440

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FFR guided PCI
Description: Patients undergo Fractional Flow measurement (FFR) followed by PCI, if the FFR is less than 0.8

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angio guided PCI
Description: Patients receive PCI without FFR measurement
Study: NCT00039013

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Study: NCT03711877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scalp cooling system
Description: Scalp cooling was initiated 30 minutes prior to each chemotherapy cycle, with scalp temperature maintained at 3°C (37°F) throughout chemotherapy and for 90 minutes to 120 minutes afterward. Temperature of scalp cooling system can be controlled constantly, the effect of reducing scalp temperature maybe better and patient tolerance maybe better. Meanwhile, there is a higher likelihood of hair retention due to a tight fit in scalp cooling system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold cap
Description: The operation of chemical cold cap is convenient and the price was low, and the economic burden of patients was not increased. But it is necessary to replace the cold cap periodically during chemotherapy, and the temperature during chemotherapy is difficult to keep constant.
Study: NCT04256304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHEinAction-Personalized Patient Engagement Plan
Description: The intervention includes two face-to-face sessions, a telephone consultation, and written home-based exercises. The first session aims to promote an awareness of patients with diabetes management, define an action plan to encourage engagement, introduce the patient to follow their strategy for the next four weeks, and encourage them to adopt the instruments with home-based exercises to reach their specified health goals. Two weeks after the first interview session, the researcher will provide telephone consultation to check the patient for their progress and support them to maintain motivation. The second session will include collecting patient's experiences and discussing the home-based exercises, re-determining the patient health engagement phase through the PHE-s®, discussing the personalized care goals by providing feedback aiming to support improvements, and setting a new engagement goal with the current status and encouraging the patient to maintain the health engagement plan.
Study: NCT02797639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-PID
Description: The program was carried out by the school occupational therapist and homeroom teachers. The Co-PID had two phases. The first phase was a 1.5 hour in-service meeting that focused on the concept of Participation.~In the second phase of the Co-PID intervention, a collaborative consultation model was used. It included eight 45-minute consultation meetings, which took place every other week over a 3-months period. The meetings took place between the occupational therapist and each teacher, with the purpose of brainstorming; thinking of activities that the teacher could implement during the lessons for enhancing participation among the students.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IS
Description: IS group included three meetings, a 1.5 hour in-service meeting focusing on the concept of participation, and two more workshop meetings aimed at sharing teachers' experience.
Study: NCT01957709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Gamma
Description: Given subcutaneously weekly for four weeks prior to surgery.
Study: NCT03587584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine
Description: Experimental

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Active Comparator
Study: NCT04142749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oltipraz
Description: Total 90mg, By mouth, TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Total 90mg, By mouth, TID
Study: NCT01111019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (r-hGH)
Description: Subjects will receive a single subcutaneous injection of recombinant human growth hormone (r-hGH) equivalent to a dose of 0.057 milligram per kilogram per day (mg/kg/day). The dose will be subsequently adjusted during the trial and subjects will be treated for at least 3 years or until near final height is reached.
Study: NCT01346774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cranberry powder capsules
Description: 2 cranberry powder capsules twice a day
Study: NCT03028584

Intervention type: BEHAVIORAL
Intervention: Survey
Description: Subjects (cancer patients and clinicians) will complete up to 2 surveys.

Intervention type: BEHAVIORAL
Intervention: Survey
Description: Subjects (cancer patients and clinicians) will complete up to 2 surveys.
Study: NCT04234763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategies to lower postprandial hyperglycemia in T2D patients
Description: T2D patients will undergo a 14-day chronic feeding trial intervention where the strategies to lower postprandial hyperglycemia will be educated. For example, to control portion of carbohydrate, incorporate low GI food and diabetes-specific formula, promote physical activity and practice consistent meal timing. After that, patients will undergo MCT again to evaluate the difference before and after the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Assess nutritional status and no active intervention is conducted.
Study: NCT03746808

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMA + App/Treatment Messages
Description: This study will develop and test a just-in-time adaptive intervention to reduce alcohol use among homeless adults. Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults with an AUD who are enrolled in shelter-based treatment. Phase II will use this information to create a risk algorithm and tailored treatment messages that anticipate and intervene to prevent alcohol use.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: EMA + App/Treatment Messages
Description: This study will develop and test a just-in-time adaptive intervention to reduce alcohol use among homeless adults. Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults with an AUD who are enrolled in shelter-based treatment. Phase II will use this information to create a risk algorithm and tailored treatment messages that anticipate and intervene to prevent alcohol use.
Study: NCT04145869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cholangiography
Description: All patients will be subjected to intraoperative fluorescent and concommitant X-ray cholangiography
Study: NCT01346774

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder capsules
Description: 2 placebo capsules twice a day
Study: NCT00630890

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation and Cyberknife radiosurgery boost and capecitabine
Description: External Beam Radiation to 45 Gy Stereotactic Body Radiotherapy with Cyberknife to 20 Gy in 5 fractions dose escalation to 25 Gy in 5 fractions, and then 30 Gy in 5 fractions Capecitabine 825 mg/m2 q12 hours taken orally 5 days per week
Study: NCT00409318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: 50 mg SC q week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC q week
Study: NCT02246439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RHB-102
Description: RHB-102, Bimodal Release Ondansetron Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study: NCT02706782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAI-meso-CART
Description: TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And meso-CART is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator
Study: NCT02255682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Q10
Study: NCT03858738

Intervention type: DEVICE
Intervention: Thermographic breast examination performed by Braster device
Description: Patient undergo contact thermography examination with the use of liquid crystal contact thermography device- Braster.
Study: NCT01790373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suubi+Adherence
Description: * Matched savings accounts/child development accounts (CDAs) for the adolescents held in a local bank.~* Financial education and workshops on asset-building, future planning, and protection from risks~* Mentorship from a young adult/near-peer~* Family-based microenterprise development training~* Medical Event Monitoring System~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling
Study: NCT03858738

Intervention type: DEVICE
Intervention: Thermographic breast examination performed by Braster device
Description: Patient undergo contact thermography examination with the use of liquid crystal contact thermography device- Braster.

Intervention type: DEVICE
Intervention: Thermographic breast examination performed by Braster device
Description: Patient undergo contact thermography examination with the use of liquid crystal contact thermography device- Braster.
Study: NCT03595631

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy plus Neurodynamic
Description: Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week. In addition, they will also receive bilateral nerve slider neurodynamic interventions targeting the median, ulnar and radial nerves.
Study: NCT01790373

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bolstered Standard of Care
Description: -Medical Event Monitoring System~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling
Study: NCT01873105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Team Educational Intervention
Description: AHRQ TeamStepps processes will be used to redesign health team discharge communication processes and an educational intervention for health care team members
Study: NCT03055091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xylitol syrup
Description: Each dose will be 5 mL of 400 g/L and subjects will receive Three to 5 doses will be given each day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each dose looks and tastes like the xylitol syrup but it is not microbial. Each dose will be 5 mL of 300 g/L of sorbitol. Three to 5 doses will be given each day.
Study: NCT04123730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fixed-dose compared to variable oxygen flow supplementation during walking
Description: At day 1 the patients will perform Walk A and Walk B in a random order:~Walk A: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with the fixed-dose (FOT). O2matic will monitor pulse rate and saturation continuously during the test.~Walk B: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with a variable oxygen flow (AOT) depending on the saturation. O2matic will monitor pulse rate and saturation continuously during the test, and adjust oxygen flow depending on the saturation.~At day 2 the patients will perform two 6 minutes walking (MWT) test in random order:~Walk C: A 6 MWT with FOT Walk D; A 6 MWT with AOT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed-dose compared to variable oxygen flow supplementation during walking
Description: At day 1 the patients will perform Walk A and Walk B in a random order:~Walk A: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with the fixed-dose (FOT). O2matic will monitor pulse rate and saturation continuously during the test.~Walk B: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with a variable oxygen flow (AOT) depending on the saturation. O2matic will monitor pulse rate and saturation continuously during the test, and adjust oxygen flow depending on the saturation.~At day 2 the patients will perform two 6 minutes walking (MWT) test in random order:~Walk C: A 6 MWT with FOT Walk D; A 6 MWT with AOT
Study: NCT03058133

Intervention type: OTHER
Group type: OTHER
Intervention: fMRI study
Description: Functional brain activations of face-voice processing during a gender task
Study: NCT03119168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone Solution
Description: Patients will be assigned randomly to take Simethicone Solution plus polyethylenglycol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylenglycol
Description: Patients in this arm will be randomly assigned to take polyethylenglycol as their regular bowel preparation
Study: NCT02170844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of BIBR 1048 MS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of BIBR 1048 MS
Study: NCT02042287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal lactic acid and glycogen gel
Description: Medical device (registration number: 10-355-717, first licensed 12.08.2010)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Oral antibiotic
Study: NCT01745588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Study: NCT03661957

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non grafted maxillary sinus floor elevation with simultaneous implant placement
Description: lateral window for sinus elevation ,membrane elevation ,implant placement , membrane for window closure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: using short dental implants for posterior atrophic maxilla
Description: placement of short dental implant with bone height below 8mm
Study: NCT04372004

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: diagnostic tests for COVID-19 infection
Description: Compare the efficacy of diagnostic tests for COVID-19 infection in detecting antibodies and viral-RNA
Study: NCT01745588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT04372004

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: diagnostic tests for COVID-19 infection
Description: Compare the efficacy of diagnostic tests for COVID-19 infection in detecting antibodies and viral-RNA

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: diagnostic tests for COVID-19 infection
Description: Compare the efficacy of diagnostic tests for COVID-19 infection in detecting antibodies and viral-RNA
Study: NCT02372253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00694447

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study: NCT01930318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parecoxib
Description: 4 groups: PCA,Placebo,Placebo-PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery; PCA,placebo,tramadol-PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol(0.1g t.i.d.) in the day 3 to day 5 after surgery;PCA,parecoxib,placebo-PCA for 2 days after operation, i.v parecoxib(40mg b.i.d.) in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery;PCA,parecoxib,celecoxib-PCA for 2 days after operation,i.v parecoxib(40mg b.i.d.) in 2 days after surgery and oral celecoxib(0.2g b.i.d.) in the day 3 to day 5 after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parecoxib
Description: 4 groups: PCA,Placebo,Placebo-PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery; PCA,placebo,tramadol-PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol(0.1g t.i.d.) in the day 3 to day 5 after surgery;PCA,parecoxib,placebo-PCA for 2 days after operation, i.v parecoxib(40mg b.i.d.) in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery;PCA,parecoxib,celecoxib-PCA for 2 days after operation,i.v parecoxib(40mg b.i.d.) in 2 days after surgery and oral celecoxib(0.2g b.i.d.) in the day 3 to day 5 after surgery
Study: NCT02812979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airvo2 with Aerogen Solo
Description: Nebulization of salbutamol with Airvo 2 and Aerogen solo
Study: NCT04145869

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cholangiography
Description: All patients will be subjected to intraoperative fluorescent and concommitant X-ray cholangiography
Study: NCT02812979

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mask
Description: Usual nebulization of salbutamol with mask

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: arm control Airvo2 without nebulization of salbutamol
Description: Airvo2 with Aerogen Solo. No nebulization of salbutamol
Study: NCT02452996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNbAC1
Description: Single dose of IMP, IV infusion
Study: NCT01745588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Study: NCT04327440

Intervention type: BIOLOGICAL
Intervention: RTS,S/AS01 malaria vaccine
Description: Malaria vaccine: RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen combined with an adjuvant. The Phase 3 trial of three doses administered to 5-17-month-olds confirmed moderate protection, with overall efficacy estimates of 50.4% against clinical malaria and 34.8% against severe malaria after three doses. Efficacy, which waned over time, was marginally improved by boosting at 18 months. The European Medicines Agency adopted a positive scientific opinion of the vaccine for use outside of the European Union. The World Health Organization has created the Malaria Vaccine Implementation Program (MVIP) and selected Malawi as one of the sites to explore the feasibility, efficacy and safety of RTS,S vaccination in the context of routine use.
Study: NCT01788280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluciclitite , PET imaging, and Bevacizumab
Description: \[18F\] Fluciclatide and PET imaging in patients with glioblastoma multiforme (GBM) to be treated with Bevacizumab
Study: NCT00694447

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Study: NCT02088424

Intervention type: OTHER
Intervention: insulin resistance(fasting glucose/fasting insulin)
Description: insulin resistance(fasting glucose/fasting insulin )

Intervention type: OTHER
Intervention: insulin resistance(fasting glucose/fasting insulin)
Description: insulin resistance(fasting glucose/fasting insulin )
Study: NCT00099788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: IV to oral transition.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV to oral transition.